{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:26:45Z","timestamp":1774045605089,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Doktor Robert Pfleger-Stiftung, Hallstadt, Germany","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The mechanistic target of rapamycin (mTOR) is elevated in prostate cancer, making this protein attractive for tumor treatment. Unfortunately, resistance towards mTOR inhibitors develops and the tumor becomes reactivated. We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Prostate cancer cells, sensitive (parental) and resistant to temsirolimus, were exposed to VPA, and tumor cell growth behavior compared. Temsirolimus resistance enhanced the number of tumor cells in the G2\/M-phase, correlating with elevated cell proliferation and clonal growth. The cell cycling proteins cdk1 and cyclin B, along with Akt-mTOR signaling increased, whereas p19, p21 and p27 decreased, compared to the parental cells. VPA significantly reduced cell growth and up-regulated the acetylated histones H3 and H4. Cdk1 and cyclin B decreased, as did phosphorylated mTOR and the mTOR sub-complex Raptor. The mTOR sub-member Rictor and phosphorylated Akt increased under VPA. Knockdown of cdk1, cyclin B, or Raptor led to significant cell growth reduction. HDAC inhibition through VPA counteracts temsirolimus resistance, probably by down-regulating cdk1, cyclin B and Raptor. Enhanced Rictor and Akt, however, may represent an undesired feedback loop, which should be considered when designing future therapeutic regimens.<\/jats:p>","DOI":"10.3390\/cancers11040566","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T11:02:53Z","timestamp":1555930973000},"page":"566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro"],"prefix":"10.3390","volume":"11","author":[{"given":"Jasmina","family":"Makarevi\u0107","sequence":"first","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Rutz","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Juengel","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Maxeiner","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix K.-H.","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Bereiter-Hahn","sequence":"additional","affiliation":[{"name":"Institute for Cell Biology and Neurosciences, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[{"name":"Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/apm.12880","article-title":"Increased levels of serum miR-148a-3p are associated with prostate cancer","volume":"126","author":"Dybos","year":"2018","journal-title":"APMIS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","article-title":"Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically","volume":"29","author":"Ryan","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00432-018-2664-y","article-title":"Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: A network meta-analysis of randomized controlled trials","volume":"144","author":"Wang","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/03007995.2017.1341869","article-title":"Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: A systematic review of the literature","volume":"33","author":"Summers","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-15-2119","article-title":"Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer","volume":"22","author":"Kato","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss","volume":"25","author":"Rodrigues","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10637-018-0578-9","article-title":"A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Graham","year":"2018","journal-title":"Invest. New Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Earwaker, P., Anderson, C., Willenbrock, F., Harris, A.L., Protheroe, A.S., and Macaulay, V.M. (2018). RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191890"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","volume":"324","author":"Juengel","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/jcmm.12299","article-title":"Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells","volume":"18","author":"Tawanaie","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67521","DOI":"10.18632\/oncotarget.11750","article-title":"Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"110016","DOI":"10.18632\/oncotarget.22454","article-title":"HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells","volume":"8","author":"Juengel","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1476-4598-13-152","article-title":"HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A","volume":"13","author":"Juengel","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Makarevi\u0107, J., Rutz, J., Juengel, E., Maxeiner, S., Mani, J., Vallo, S., Tsaur, I., Roos, F., Chun, F.K., and Blaheta, R.A. (2018). HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression. Cells, 7.","DOI":"10.3390\/cells7090129"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2011.08.026","article-title":"The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line","volume":"313","author":"Tsaur","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s10038-017-0371-1","article-title":"Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis","volume":"63","author":"Yamada","year":"2018","journal-title":"J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/bjc.2017.191","article-title":"Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer","volume":"117","author":"Goto","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1202","DOI":"10.1111\/j.1464-410X.2012.11534.x","article-title":"Molecular phenotyping of circulating tumour cells in patients with prostate cancer: Prediction of distant metastases","volume":"110","author":"Giesing","year":"2012","journal-title":"BJU Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00109-010-0635-0","article-title":"Identification of p27\/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer","volume":"88","author":"Chen","year":"2010","journal-title":"J. Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17216","DOI":"10.18632\/oncotarget.15303","article-title":"Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53\/p21WAF1\/CIP1 and p27KIP1 pathway","volume":"8","author":"Singh","year":"2017","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1038\/onc.2015.444","article-title":"HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer","volume":"35","author":"Ruscetti","year":"2016","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature11043","article-title":"SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation","volume":"487","author":"Barber","year":"2012","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1093\/nar\/gkv394","article-title":"MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer","volume":"43","author":"Wang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ejmech.2015.08.024","article-title":"Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics","volume":"102","author":"Sociali","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jnutbio.2016.10.019","article-title":"A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27","volume":"40","author":"Huang","year":"2017","journal-title":"J. Nutr. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s12010-017-2684-0","article-title":"Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells","volume":"185","author":"Sajadpoor","year":"2018","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_28","first-page":"2202","article-title":"Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: A Connectivity Mapping analysis and an experimental study","volume":"5","author":"Zhuo","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_29","first-page":"1299","article-title":"Valproic acid overcomes transforming growth factor-\u03b2-mediated sorafenib resistance in hepatocellular carcinoma","volume":"7","author":"Matsuda","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11523-015-0370-0","article-title":"The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX","volume":"10","author":"Wang","year":"2015","journal-title":"Target. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","article-title":"Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium","volume":"96","author":"Blaheta","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1073\/pnas.1607768113","article-title":"Mitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformation","volume":"113","author":"Cheng","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/jcmm.13091","article-title":"Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis","volume":"21","author":"Li","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1172\/JCI91144","article-title":"AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis","volume":"127","author":"Li","year":"2017","journal-title":"J. Clin. Invest."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oneyama, C., Kito, Y., Asai, R., Ikeda, J., Yoshida, T., Okuzaki, D., Kokuda, R., Kakumoto, K., Takayama, K., and Inoue, S. (2013). MiR-424\/503-mediated Rictor upregulation promotes tumor progression. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080300"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Xia","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13041-018-0423-2","article-title":"Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero","volume":"12","author":"Kobayashi","year":"2019","journal-title":"Mol. Brain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbr.2017.04.015","article-title":"Antidepressant-like effect of valproic acid-Possible involvement of PI3K\/Akt\/mTOR pathway","volume":"329","author":"Lima","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Juengel, E., Makarevi\u0107, J., Tsaur, I., Bartsch, G., Nelson, K., Haferkamp, A., and Blaheta, R.A. (2013). Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053100"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10552-016-0737-2","article-title":"Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: Apopulation-based case-control study","volume":"27","author":"Salminen","year":"2016","journal-title":"Cancer Causes Control."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1756287215597637","article-title":"Histone deacetylase inhibitors in castration-resistant prostate cancer: Molecular mechanism of action and recent clinical trials","volume":"7","author":"Kaushik","year":"2015","journal-title":"Ther. Adv. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10637-015-0252-4","article-title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","volume":"33","author":"Eigl","year":"2015","journal-title":"Invest. New Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"60169","DOI":"10.18632\/oncotarget.11109","article-title":"Superior efficacy of co-treatment with the dual PI3K\/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC","volume":"7","author":"Piao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10549-014-2877-y","article-title":"mTORC1\/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms","volume":"144","author":"Yevtushenko","year":"2014","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/4\/566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:46:53Z","timestamp":1760186813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/4\/566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["cancers11040566"],"URL":"https:\/\/doi.org\/10.3390\/cancers11040566","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]}}}